RT Journal Article
SR Electronic
T1 Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP S42
OP S47
DO 10.1097/IGC.0000000000000249
VO 24
IS Supp 3
A1 Isabelle Ray-Coquard
A1 Jubilee Brown
A1 Philipp Harter
A1 Diane M. Provencher
A1 Peter C. Fong
A1 Johanna Maenpaa
A1 Jonathan A. Ledermann
A1 Gunter Emons
A1 Dominique Berton Rigaud
A1 Rosalind M. Glasspool
A1 Delia Mezzanzanica
A1 Nicoletta Colombo
YR 2014
UL http://ijgc.bmj.com/content/24/Supp_3/S42.abstract
AB Sex cord stromal tumors (SCST) are rare cancers of the ovarian area in adults. They constitute a heterogeneous group of tumors that develop from the sex cords and the ovarian stroma. These tumors are detected typically at an early stage, and they may recur as late as 30 years after the initial treatment. Because 70% of the patients present with stage I tumors, surgery represents the most important therapeutic arm. There are no data to support any kind of postoperative adjuvant treatment for patients with stage IA or IB SCSTs, given the indolent nature of these neoplasms and the overall good prognosis. The long natural history of the disease may lead to repeated surgical procedure should a relapse occurs. Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease, with an overall response rate of 63% to 80%. The indolent nature of SCSTs with the tendency for late recurrence requires long-term follow-up.